Angiotensinogen Gene Polymorphisms: Relationship to Blood Pressure Response to Antihypertensive Treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) Trial

American Journal of Hypertension

Volumn 17, Issue 1, 2004, Pages 8-13

  Kurland, Lisa ^a   Liljedahl, Ulrika ^a   Karlsson, Julia ^a   Kahan, Thomas ^b   Malmqvist, Karin ^b   Melhus, Håkan ^a   Syvänen, Ann Christine ^a   Lind, Lars ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensinogen; Atenolol; Drug treatment; Genes; Hypertension; Irbesartan; Single nucleotide polymorphisms

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; IRBESARTAN; NUCLEOTIDE;

ADULT; ALLELE; ARTICLE; BLOOD PRESSURE; BORDERLINE HYPERTENSION; CLINICAL TRIAL; DISEASE SEVERITY; DNA MICROARRAY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE SEQUENCE; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PATIENT; PRIORITY JOURNAL; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

EID: 0346059332     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.09.009     Document Type: Article

References (21)

1. Kaplan NM: Clinical Hypertension. Williams & Wilkens, 1998: 205-214.
2. Danser AH, Schunkert H: Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000;410:303-316.
3. Wang JG, Staessen JA: Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000;410:289-302.
4. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nyström F, Öhman KP, Osbakken MD, Östergren J: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-1176.
5. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Öhman P, Nyström F, Hägg A, Lind L: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type I antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-1787.
6. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Öhman P, Nyström F, Hägg A, Lind L: Aldosterone synthase (CYP11B2) -344 C/T is related to antihypertensive response. Am J Hypertens 2002;15:387-393.
7. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, Alonso DR: Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986;57:1388-1393.
8. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, Nyström F, Lind L, Syvänen A-C: A microarray minisequencing system for pharmacogeentic profiling of antihypertensive drug response. Pharmacogenetics 2003;13:7-17.
9. Smithies O, Kim HS: Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 1994;91:3612-3615.
10. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O: Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995;92:2735-2739.
11. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt CH, Hopkins PN, Williams RRR, Lalouel J-M, Corvol P: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.
12. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM: Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997;30:1331-1337.
13. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R: M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 1999;17:9-17.
14. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel J-M: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786-1797.
15. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo A-P, Hata A, Corvol P, Lalouel J-M: Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 1997;60:1448-1460.
16. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A: Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension 1999;33:108-115.
17. Sato N, Katsuya T, Rakugi H, Takami S, Nakata Y, Miki T, Higaki J, Ogihara T: Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertension 1997;30:321-325.
18. Buhler FR, Laragh JH, Baer L, Vaughan ED, Jr., Brunner HR: Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287:1209-1214.
19. Prichard BNC, Cruickshank JM: Beta blockade in hypertension: past, present and future, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. Raven Press, New York, 1995, pp 2827-2859.
20. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-459.
21. Malmqvist K, Öhman KP, Nyström F, Lind L, Kahan T: Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension. J Cardiovasc Pharmacol 2003;42:719-726.